Research led by Manali Kamdar, MD, at the University of Colorado Cancer Center helped prompt the FDA to shorten monitoring requirements for CAR T-cell therapy. The change is expected to reduce barriers and expand access for lymphoma patients who previously faced major logistical challenges.